Colon News and Research

RSS

MicroRNAs control levels of Myc protein in Drosophila: Researchers

In all cancers, whether in kidney, breast, lung, colon, skin or any other tissue, cells show high Myc protein levels. Excess Myc causes cells to multiply in an exaggerated manner, giving rise to the development of tumours. One of the most pressing questions about Myc is how healthy cells keep the expression of this protein in check.

21 Apr 2010

Positive preclinical pharmacokinetic data for XMT-1001 presented at AACR 2010

Mersana Therapeutics, a platform-based cancer therapeutics company, announced today positive preclinical pharmacokinetic data for its lead development candidate, XMT-1001, which is currently in a Phase 1 clinical trial in patients with advanced solid tumors. The results were presented in a poster session at the AACR 101st Annual Meeting 2010 in Washington, DC, held April 17-21, 2010.

21 Apr 2010

Immunomedics reports study results of antibody-SN-38 conjugates for targeted cancer chemotherapy

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, reported today at the 101st Annual Meeting of the American Association for Cancer Research (AACR) results from two studies aimed at improving the design of antibody-SN-38 conjugates for targeted cancer chemotherapy.

21 Apr 2010

Gene test predicts statins' effectiveness in reducing risk of colorectal cancer

A genetic test can help determine in which patients cholesterol-lowering statin drugs might have the most benefit in also reducing the risk of colorectal cancer, a new study from researchers at the University of Michigan Comprehensive Cancer Center finds.

21 Apr 2010

Vitamin D intake from foods, supplements may not predict relationship between cancer and vitamin D

Vitamin supplements, diet, geographic location, demographic information or lifestyle, independently or in combination, cannot accurately predict vitamin D concentrations in blood, researchers at the University at Buffalo have found.

21 Apr 2010

MUC1 expression indicates progression of pediatric inflammatory bowel disease

Millions of people are afflicted with inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, and 30 percent of new cases occur in childhood. Mucin 1, an epithelial mucin that has been shown to elicit both an immune response and to have altered glycosylation in disease, may be a noninvasive indicator of the progression of these illnesses.

20 Apr 2010

Blood test to determine inflammation levels in body may help assess colon cancer risk: Study

A blood test used to determine the level of inflammation in the body may offer some help in assessing colon cancer risk, according to results of a study to be presented by Vanderbilt-Ingram Cancer Center's Gong Yang, M.D., MPH, at the 101st Annual Meeting of the American Association for Cancer Research.

20 Apr 2010

CryoSTAT cold therapy for hemorrhoids

Revolutionary new CryoSTAT is here to put the fire out when it comes to hemorrhoids by treating them on contact with cold therapy which has a proven track record of providing instant relief with no mess.

20 Apr 2010

Researchers use genistein to improve outlook of pancreatic cancer

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented data at the American Association for Cancer Research's 101st Annual Meeting 2010 that shows when genistein, a component of soy, is paired with the FDA-approved drug oxaliplatin, pancreatic cancer cells become more sensitive to chemotherapy.

20 Apr 2010

First case of treating cystic fibrosis and Crohn's disease with infliximab

Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in Caucasian children; it has an incidence of 1 case in every 2500 children born alive. CF involves an anomalous function of the exocrine glands, caused by a mutation of a gene (cystic fibrosis transmembrane conductance regulator, CFTR) located on chromosome 7, which codes for a protein involved in ion transport through the cell membrane.

20 Apr 2010

UAB researchers discover four miRNAs to assess survival rate of colorectal cancer patients

Researchers at the University of Alabama at Birmingham Department of Pathology have discovered a set of four biomarkers that will help predict which patients are more likely to develop aggressive colorectal cancer and which are not. The findings also shed light on the genetics that result in worse colorectal cancer-treatment outcomes for African-Americans, compared with Caucasians, the researchers said.

20 Apr 2010

New research shows link between infection-related diseases and risk of cancer

New research is emerging that suggests a link between infection-related diseases and risk of cancer, according to findings presented here at the American Association for Cancer Research 101st Annual Meeting 2010.

20 Apr 2010

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported the development of a novel protein complex, designated as E1-L-thP1, for targeted delivery of small interfering ribonucleic acids (siRNAs) to diverse solid cancers.

19 Apr 2010

Biomarkers to help predict development of aggressive colorectal cancer discovered

Researchers at the University of Alabama at Birmingham (UAB) Department of Pathology have discovered a set of four biomarkers that will help predict which patients are more likely to develop aggressive colorectal cancer and which are not. The findings also shed light on the genetics that result in worse colorectal cancer-treatment outcomes for African-Americans, compared with Caucasians, the researchers said.

19 Apr 2010

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

At the American Association for Cancer Research 101st Annual Meeting 2010, scientists and clinicians will present more than 6,300 abstracts dealing with innovative aspects of biology, technology and emerging therapies.

19 Apr 2010

Study reveals increased risk for cancer among Latino populations

New findings from epidemiology and observational studies show an increased risk for cancer among Latino populations, but unique demographic characteristics suggest the problem may be worse than currently known.

19 Apr 2010

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Findings published today in The New England Journal of Medicine from a first-of-its-kind comparator trial evaluating the anti-tumor necrosis factor (TNF)-alpha biologic treatment REMICADE (infliximab) in the treatment of moderately to severely active Crohn's disease in patients who were naive to immunomodulator and biologic therapy, showed that a significantly greater proportion of patients receiving REMICADE achieved steroid-free remission and mucosal healing compared with patients receiving azathioprine.

16 Apr 2010

Exclusive licensing practices slows innovation in gene testing market

Exclusive licenses to gene patents, most of which are held by academic institutions and based on taxpayer-funded research, do more to block competition in the gene testing market than to spur the development of new technologies for gauging disease risk, say researchers at the Duke Institute for Genome Sciences & Policy (IGSP).

15 Apr 2010

Decoding genomes from 25,000 cancer samples

The International Cancer Genome Consortium (ICGC) today set out its bold plan to decode the genomes from 25,000 cancer samples and create a resource of freely available data that will help cancer researchers around the world. The publication outlines research design and projects as well as the important ethical framework for this science.

15 Apr 2010

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Pfizer Oncology announced today that it will present new data from the company's pipeline, including two novel, dual PI3K/mTOR inhibitors (PF-04691502 and PKI-587, also known as PF-05212384); crizotinib (PF-02341066), an ALK inhibitor that also inhibits c-MET; and PF-04605412, an anti-α5β1 inhibitor.

15 Apr 2010

Colon News and Research

MicroRNAs control levels of Myc protein in Drosophila: Researchers

Positive preclinical pharmacokinetic data for XMT-1001 presented at AACR 2010

Immunomedics reports study results of antibody-SN-38 conjugates for targeted cancer chemotherapy

Gene test predicts statins' effectiveness in reducing risk of colorectal cancer

Vitamin D intake from foods, supplements may not predict relationship between cancer and vitamin D

MUC1 expression indicates progression of pediatric inflammatory bowel disease

Blood test to determine inflammation levels in body may help assess colon cancer risk: Study

CryoSTAT cold therapy for hemorrhoids

Researchers use genistein to improve outlook of pancreatic cancer

First case of treating cystic fibrosis and Crohn's disease with infliximab

UAB researchers discover four miRNAs to assess survival rate of colorectal cancer patients

New research shows link between infection-related diseases and risk of cancer

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Biomarkers to help predict development of aggressive colorectal cancer discovered

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

Study reveals increased risk for cancer among Latino populations

Results of study comparing REMICADE to azathioprine for Crohn's disease published

Exclusive licensing practices slows innovation in gene testing market

Decoding genomes from 25,000 cancer samples

New data from Pfizer Oncology's pipeline to be presented at AACR 2010

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News